ATE363070T1 - Auswertung von biologischen mitteln in lebenden zielzellen - Google Patents

Auswertung von biologischen mitteln in lebenden zielzellen

Info

Publication number
ATE363070T1
ATE363070T1 AT00985423T AT00985423T ATE363070T1 AT E363070 T1 ATE363070 T1 AT E363070T1 AT 00985423 T AT00985423 T AT 00985423T AT 00985423 T AT00985423 T AT 00985423T AT E363070 T1 ATE363070 T1 AT E363070T1
Authority
AT
Austria
Prior art keywords
target cells
biological agents
evaluation
living target
living
Prior art date
Application number
AT00985423T
Other languages
English (en)
Inventor
Manuel Vega
Original Assignee
Nautilus Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nautilus Biotech filed Critical Nautilus Biotech
Application granted granted Critical
Publication of ATE363070T1 publication Critical patent/ATE363070T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00985423T 1999-12-16 2000-12-13 Auswertung von biologischen mitteln in lebenden zielzellen ATE363070T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9915884A FR2802645B1 (fr) 1999-12-16 1999-12-16 Methode d'evaluation de la performance d'un ensemble d'agents biologiques dans des cellules cibles vivantes et ses applications

Publications (1)

Publication Number Publication Date
ATE363070T1 true ATE363070T1 (de) 2007-06-15

Family

ID=9553337

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00985423T ATE363070T1 (de) 1999-12-16 2000-12-13 Auswertung von biologischen mitteln in lebenden zielzellen

Country Status (6)

Country Link
US (1) US20030129584A1 (de)
EP (1) EP1244912B1 (de)
AT (1) ATE363070T1 (de)
DE (1) DE60034966D1 (de)
FR (1) FR2802645B1 (de)
WO (1) WO2001044809A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2808804B1 (fr) * 2000-05-09 2002-08-02 Nautilus Biotech Procede de determination du titre d'agents biologiques en temps reel dans des cellules cibles vivantes et ses applications
US20030129203A1 (en) * 2001-08-27 2003-07-10 Nautilus Biotech S.A. Mutant recombinant adeno-associated viruses
US7647184B2 (en) 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
US20050202438A1 (en) * 2002-09-09 2005-09-15 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
DE60332358D1 (de) 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
US20060020396A1 (en) * 2002-09-09 2006-01-26 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
US20060251619A1 (en) * 2005-05-04 2006-11-09 Gilles Borrelly Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides
WO2007110231A2 (en) * 2006-03-28 2007-10-04 Nautilus Biotech, S.A. MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
US8383388B2 (en) 2006-06-19 2013-02-26 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
KR101248252B1 (ko) 2006-11-28 2013-03-27 한올바이오파마주식회사 변형된 에리스로포이에틴 폴리펩티드와 이의 치료용 용도
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
US10943676B2 (en) 2010-06-08 2021-03-09 Cerner Innovation, Inc. Healthcare information technology system for predicting or preventing readmissions
GB201411060D0 (en) * 2014-06-20 2014-08-06 Oncimmune Ltd Improved immunoassay method

Also Published As

Publication number Publication date
EP1244912A2 (de) 2002-10-02
FR2802645A1 (fr) 2001-06-22
EP1244912B1 (de) 2007-05-23
US20030129584A1 (en) 2003-07-10
WO2001044809A2 (fr) 2001-06-21
FR2802645B1 (fr) 2002-03-08
WO2001044809A3 (fr) 2001-12-20
DE60034966D1 (de) 2007-07-05

Similar Documents

Publication Publication Date Title
FR19C1020I1 (fr) Nouvelles molecules b7-4 et leurs utilisations
ATE363070T1 (de) Auswertung von biologischen mitteln in lebenden zielzellen
ATE397752T1 (de) Verfahren und verwendung von anordungen von proteinfixierungsmitteln
ATE549347T1 (de) Gene von säugetiere, und damit verbundene reagentien, methoden
WO2004041865A3 (en) Stabilized single domain antibodies
ATE476654T1 (de) Plattform für protein-profiling
ATE517922T1 (de) Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
CY1111006T1 (el) Εκριμματαση ασθενειας alzheimer
DE69813158D1 (de) Assays zur Bestimmung von Proteinfragmenten in biologischen Medien
DK0961780T3 (da) Proteinmarkörer for lungecancer og anvendelse deraf
IS5887A (is) Interferón-beta bræðsluprótín og notkun þeirra
DK0692025T3 (da) Gærceller, der er konstrueret således, at de producerer surrogater for proteiner i feromonsystemet, og anvendelser deraf
DK1650219T3 (da) Humane TOLL-homologer
ATE532533T1 (de) Von antikörpern abgeleitete vektoren für den transfer von substanzen in zellen
DE69734829D1 (de) Infektiöse pseudovirale papillomavirus partikel
ATE311443T1 (de) Methoden zur durchforstung (screenen) von proteinen
DE60114018D1 (de) Von zellen präsentierte peptide
ATE384263T1 (de) Verfahren zur bestimmung von biologischen agenzien in lebenden zielzellen
WO1999047639A3 (en) Staphylococcus aureus genes and polypeptides
DK0960336T3 (da) Peptidreagens til påvisning af humant cytomelagovirus (CMV)
WO2002048403A3 (en) Multiplexed protein expression and activity assay
NO972063L (no) Isolert BMP-reseptorkinaseprotein, DNA-sekvens, rekombinant ekspresjonsvektor samt vertscelle
AU4908799A (en) Determination of the hydrophobic pulmonary surfactant protein sp-c
DE69333304D1 (de) Erhöhte produktion von sekretierten proteinen durch rekombinante eukaryotische zellen
DE60042922D1 (de) Virale expressionsvektoren für pflanzen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties